Erlotinib (Tarceva) for advanced non-small cell lung cancer

Med Lett Drugs Ther. 2005 Mar 28;47(1205):25-6.

Abstract

Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.

Publication types

  • Clinical Trial

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Diarrhea / chemically induced
  • Erlotinib Hydrochloride
  • Exanthema / chemically induced
  • Humans
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*

Substances

  • Quinazolines
  • Erlotinib Hydrochloride